Mazdutide is a synthetic peptide commercialized by Innovent Biologics, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 20 clinical trials, of which 13 were completed, 6 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Mazdutide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Mazdutide is expected to reach an annual total of $327 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Mazdutide Overview
Mazdutide (LY-3305677) is under development for the treatment of type 2 diabetes, obesity, non-alcoholic steatohepatitis (NASH) and non alcoholic fatty liver disease (NAFLD). It is administered through subcutaneous route. The drug candidate is a next generation oxyntomodulin and targets glucagon like peptide 1 receptor (GLP1R) and glucagon receptor (GCGR). It is a new molecular entity (NME).
Innovent Biologics Overview
Innovent Biologics is a biopharmaceutical company that carries out the research, development and manufacturing of monoclonal antibodies. It provides products for various diseases such as metabolic, cancer, autoimmune diseases and other therapeutic areas. The company’s oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, olverembatinib, ramucirumab, and others. Its autoimmune drugs are adalimumab injection, IBI-353, IBI-112 and IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311
The company reported revenues of (Renminbi) CNY6,206.1 million for the fiscal year ended December 2023 (FY2023), an increase of 36.2% over FY2022. The operating loss of the company was CNY1,045.8 million in FY2023, compared to an operating loss of CNY2,068.8 million in FY2022. The net loss of the company was CNY1,027.9 million in FY2023, compared to a net loss of CNY2,179.3 million in FY2022.
For a complete picture of Mazdutide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
